Cargando…
Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer
Pancreatic cancer is a devastating disease with poor survival outcomes. Recent studies have shown that the addition of radiotherapy to chemotherapy in the setting of locally advanced pancreatic cancer did not improve overall survival outcome. These studies commonly utilize conventional radiotherapy...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876650/ https://www.ncbi.nlm.nih.gov/pubmed/29547526 http://dx.doi.org/10.3390/cancers10030075 |
_version_ | 1783310554951057408 |
---|---|
author | Ng, Sweet Ping Herman, Joseph M. |
author_facet | Ng, Sweet Ping Herman, Joseph M. |
author_sort | Ng, Sweet Ping |
collection | PubMed |
description | Pancreatic cancer is a devastating disease with poor survival outcomes. Recent studies have shown that the addition of radiotherapy to chemotherapy in the setting of locally advanced pancreatic cancer did not improve overall survival outcome. These studies commonly utilize conventional radiotherapy treatment fractionation and technique (typically 3-D conformal radiotherapy or intensity modulated radiotherapy). Although no clear benefit in overall survival was demonstrated in those studies, those who received radiotherapy did have a clear benefit in terms of local control. Therefore, there is increasing interest in exploring different techniques and/or modality of radiotherapy and dose/fractionation. Stereotactic radiotherapy, which employs a hypofractionated regimen, has the potential advantage of delivering a high dose of radiation to the tumor in a short period of time (typically over 5 days) with minimal dose to the surrounding normal structures. Particle therapy such as proton and carbon ion therapy are being explored as potential radiation modality that could cause greater biological damage to the tumor compared to photon treatment, with rapid dose falloff resulting in minimal to no dose to adjacent structures. This review will discuss the current literature and emerging roles of stereotactic radiotherapy and particle therapy in pancreatic cancer. |
format | Online Article Text |
id | pubmed-5876650 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-58766502018-04-09 Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer Ng, Sweet Ping Herman, Joseph M. Cancers (Basel) Review Pancreatic cancer is a devastating disease with poor survival outcomes. Recent studies have shown that the addition of radiotherapy to chemotherapy in the setting of locally advanced pancreatic cancer did not improve overall survival outcome. These studies commonly utilize conventional radiotherapy treatment fractionation and technique (typically 3-D conformal radiotherapy or intensity modulated radiotherapy). Although no clear benefit in overall survival was demonstrated in those studies, those who received radiotherapy did have a clear benefit in terms of local control. Therefore, there is increasing interest in exploring different techniques and/or modality of radiotherapy and dose/fractionation. Stereotactic radiotherapy, which employs a hypofractionated regimen, has the potential advantage of delivering a high dose of radiation to the tumor in a short period of time (typically over 5 days) with minimal dose to the surrounding normal structures. Particle therapy such as proton and carbon ion therapy are being explored as potential radiation modality that could cause greater biological damage to the tumor compared to photon treatment, with rapid dose falloff resulting in minimal to no dose to adjacent structures. This review will discuss the current literature and emerging roles of stereotactic radiotherapy and particle therapy in pancreatic cancer. MDPI 2018-03-16 /pmc/articles/PMC5876650/ /pubmed/29547526 http://dx.doi.org/10.3390/cancers10030075 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ng, Sweet Ping Herman, Joseph M. Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer |
title | Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer |
title_full | Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer |
title_fullStr | Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer |
title_full_unstemmed | Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer |
title_short | Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer |
title_sort | stereotactic radiotherapy and particle therapy for pancreatic cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876650/ https://www.ncbi.nlm.nih.gov/pubmed/29547526 http://dx.doi.org/10.3390/cancers10030075 |
work_keys_str_mv | AT ngsweetping stereotacticradiotherapyandparticletherapyforpancreaticcancer AT hermanjosephm stereotacticradiotherapyandparticletherapyforpancreaticcancer |